China life insurance: Can t you see higher short-term rates?

Transcription

1 Global Markets Research ANCHOR REPORT China life insurance: Can t you see higher short-term rates? Top pick Ping An is only Chinese financial firm with full retail financial services exposure Heading into a deregulated environment for deposit rates in 214, we believe investors have not fully discounted the challenges ahead for life insurers. As long as short-term interest rates remain higher than long-term ones, the opportunity cost to customers will keep sales under pressure as life insurers longer-dated assets fail to offer competitive yields. We expect surrender rates to rise more than expected once deposit rates deregulate further by 2Q14, and the continuing struggle between margin and volume will continue to hurt life insurers margins. Ping An is our only Buy. Its higher renewal premiums, highest organic EV/VNB growth and high beta make it most resilient to the tight liquidity environment, while offering leverage to the A-share market. We downgrade both China Life and CPIC to Reduce. 2 January 214 Research analysts China Insurance David Chung - NIHK [email protected] Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Key analysis in this anchor report includes: Latest updates on business mix and asset-liability trends Updated company notes on Ping An, China Life, CPIC and AIA See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

2 China life insurance EQUITY: INSURANCE Can t you see higher short-term rates? Top pick Ping An is only Chinese financial firm with full retail financial services exposure Bears on life as long as short-term yields are above long-term ones Both investors and life insurers themselves are warming to 214. However, we are adamant life insurers will struggle as long as short-term yields remain above long-term ones, simply because their assets are longer dated and their yields cannot compete. We expect surrenders to surprise on the upside once deposit rates deregulate further by 2Q. As life insurance growth is still lagging that of trust loans, bank loans and even total social financing, volume growth is important so that life insurance doesn't shrink further in terms of market share of financial assets, which is important in garnering policy support. Thus we reiterate our view that the struggle between balance and volume is still there, despite the life insurers themselves mostly guiding that the focus is on margins. We think the only upside risk is a rebound in A-shares, but on this basis we would prefer the brokers given their policy tailwinds. Ping An 214 is the year a valuation premium will emerge Ping An is our top pick within the sector, because it is the only provider that can offer the full spectrum of retail financial services (insurance, banking and investments) within Chinese financials. Its organic EV and VNB growth rates are also the fastest within the three life insurers we cover. Given its traditional focus on the agency channel, it is also much less susceptible to surrenders. Its renewal premiums are also the highest, implying there is no need to sell high cash value and low-margin bancassurance products to offset maturity and surrender payments. Our analysis also indicates Ping An has a higher beta, and hence offers more leverage to the index. Finally, at current valuations of 1.1x FY14F P/EV, Ping An is only trading near par with China Life and CPIC, which are both at 1.1x as well. We believe 214 is the year that Ping An will outperform and trade at a premium to peers. Global Markets Research 2 January 214 Anchor themes Equity markets have yet to fully discount for the negative impact that rising deposit rates would have on life insurers. Additionally, we believe as long as short-term rates remain above long-term ones, the operating environment for life insurers will remain difficult. Nomura vs consensus Our FY14F earnings forecasts are on average 2% lower than consensus. Research analysts China Insurance David Chung - NIHK [email protected] Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Q is as good as it gets; switch from insurers to banks by 2Q Within insurance, we prefer life over non-life, and reiterate our Reduce rating on PICC P&C (PICC Property & Casualty (2328 HK, Reduce) - Downgrade from Buy to Reduce). For life, we understand there is a focus on volume in 1Q14, and so would not be surprised if newsflow of high growth in sales dominates the quarter. However, we would recommend investors sell into any strength as these products have low margins. We would advise switching to banks by 2Q, when their valuations may well reach a near-term trough. Fig. 1: Stocks for action Bloomberg TP Current Potential up/ Company ticker Rating (HKD) price (HKD) downside (%) China (H-share) Ping An 2318 HK Buy China Life 2628 HK Reduce (12) CPIC 261 HK Reduce (8) Note: pricing as of 17 January 214. Source: Bloomberg, Nomura research See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

3 Nomura China life insurance 2 January 214 Contents 3 Too early to be complacent as new challenges are on the way 7 Volume growth to ensure share to financial assets is maintained 12 Ping An Insurance Group 18 China Life Insurance 23 China Pacific Insurance 28 AIA 35 Appendix A-1 2

4 Nomura China life insurance 2 January 214 Too early to be complacent as new challenges are on the way In theory, life insurers can generate returns to shareholders through three spreads: investment, expense and mortality. Life insurers usually generate the most spread from investment, but with funding costs largely driven by high short-term rates and given the lacklustre A-share market, life insurers have shown over the last few years that they have struggled to deliver an investment spread to shareholders. We also see pressure on the expense spread as the industry struggles to attract new talent to its agency force, while banks bargaining power on commission rates also appears to be rising. While online is proving itself a much cheaper intermediary to distribute simple wealth management products, we remain sceptical as to its ability to distribute higher-margin long-term products. Mortality is traditionally the metric with the lowest spread, due to competition, in our view, and there is probably limited upside as life insurers need to increase their protection coverage over time. Fig. 2: Valuation table Bloomberg Rating TP Current price Potential upside/ Mkt cap P/EV (x) P/B (x) P/E (x) Div. Yield ROE ROA ticker (HKD) (HKD) downside (USDmn) 13F 14F 15F 13F 14F 15F 13F 14F 15F 13F 14F 15F 13F 14F 15F 13F 14F 15F China insurers China Life 2628 HK Reduce % 71, % 2.4% 2.8% 12.1% 13.2% 14.3% 1.4% 1.5% 1.6% Ping An 2318 HK Buy % 6, % 1.5% 1.7% 17.1% 17.2% 17.1% 1.% 1.% 1.% CPIC 261 HK Reduce % 27, % 2.1% 2.5% 1.2% 11.% 11.9% 1.4% 1.5% 1.5% PICC P&C 2328 HK Reduce % 18,244 na na na % 3.% 3.2% 2.4% 17.4% 16.1% 3.3% 2.9% 2.7% Sector mean 18, % 2.1% 2.4% 14.4% 14.7% 15.1% 1.5% 1.5% 1.5% China banks ABC 1288 HK Neutral % 128,382 na na na % 6.9% 7.4% 19.9% 19.% 17.9% 1.1% 1.1% 1.% ICBC 1398 HK Buy % 23,753 na na na % 7.6% 8.2% 21.7% 2.5% 19.3% 1.4% 1.4% 1.4% CCB 939 HK Buy % 176,428 na na na % 7.5% 7.9% 21.2% 19.8% 18.4% 1.4% 1.4% 1.3% BOC 3988 HK Buy % 116,793 na na na % 7.7% 8.1% 17.2% 16.2% 15.2% 1.1% 1.1% 1.1% BOCOM 3328 HK Neutral % 47,611 na na na % 5.3% 5.4% 15.4% 14.3% 12.9% 1.1% 1.%.9% CMB 3968 HK Buy % 44,625 na na na % 5.5% 5.9% 2.7% 18.6% 17.8% 1.3% 1.3% 1.2% CITIC Bank 998 HK Buy % 26,34 na na na % 6.1% 6.4% 16.2% 15.5% 14.5% 1.1% 1.% 1.% Minsheng 1988 HK Reduce % 32,253 na na na % 5.4% 5.9% 21.3% 2.3% 19.3% 1.1% 1.1% 1.1% CRCB 3618 HK Buy % 4,11 na na na % 8.1% 9.% 17.6% 17.3% 17.% 1.3% 1.2% 1.1% Sector mean 86,698 na na na % 7.1% 7.5% 2.% 18.7% 17.6% 1.3% 1.2% 1.2% China AMC Cinda 1359 HK Buy % 23,937 na na na % 1.8% 2.2% 12.7% 12.6% 14.% 2.9% 2.8% 2.8% China brokers Citics Secs 63 HK Buy % 21,729 na na na na na 1.6% 2.% na 9.5% 11.% na 4.7% 5.2% na Haitong Secs 6837 HK Buy % 16,8 na na na na na 1.5% 1.8% na 7.2% 8.5% na 3.3% 3.7% na Sector mean 18,868 na na na na na 1.6% 1.9% na 8.5% 1.% na 4.1% 4.5% na Note: pricing as of 17 January 214 Source: Bloomberg, Nomura research Life insurers are trading at the higher end of their historical range against banks since 2H13. In our view, this is because investors are not discounting enough the challenges ahead for life insurers relative to banks under a deregulated rate environment. 3

5 Nomura China life insurance 2 January 214 Fig. 3: China life insurers sector P/EV relative to China banks P/BV (x) Insurers vs banks Avg. -1SD +1SD Jun-5 Oct-5 Feb-6 Jun-6 Oct-6 Feb-7 Jun-7 Oct-7 Feb-8 Jun-8 Oct-8 Feb-9 Jun-9 Oct-9 Feb-1 Jun-1 Oct-1 Feb-11 Jun-11 Oct-11 Feb-12 Jun-12 Oct-12 Feb-13 Jun-13 Oct-13 Source: Bloomberg, Nomura research While life insurers valuations have continued to de-rate since FY11, we do not see any near-term recovery in 214. In fact, we believe the trading range will be shifted downward over time. Fig. 4: China life insurers sector 12m forward P/EV Fig. 5: China Life 12m forward P/EV (x) 3. P/EV Avg. -1SD +1SD (x) P/EV Avg. -1SD +1SD Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14.5 Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 Source: Bloomberg, Nomura research Source: Bloomberg, Nomura research Fig. 6: Ping An 12m forward P/EV Fig. 7: CPIC 12m forward P/EV (x) 3. P/EV Avg. -1SD +1SD (x) 3. P/EV Avg. -1SD +1SD Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14.5 Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 Source: Bloomberg, Nomura research Source: Bloomberg, Nomura research 4

6 Nomura China life insurance 2 January 214 We are expecting very modest growth for NBV over the next couple of years. Fig. 8: Key assumptions China Life Ping An CPIC (%) FY13F FY14F FY15F FY13F FY14F FY15F FY13F FY14F FY15F VNB growth EV growth FYP growth NPAT growth Source: Nomura estimates Market yet to discount the impact of deposit rate deregulation to life insurers In our view, the imminent deposit rate deregulation will clearly put more pressure on life insurance sales as banks increase their deposit rates. One of the key issues for life insurance sales in China is that the short-term perceived risk-free yield is too high for life insurance products to compete. Given most people do not think they will die in the very near future, people think they are better off investing at high yields in the short term, then consider perhaps buying life insurance later. The rising deposit rate will clearly exacerbate this issue and this is something that we believe the market has yet to discount for. That is, they have well discounted this in for banks but not for insurers. Tight liquidity environment will continue to affect new business growth Additionally, we note the continued competition for liability-side funding, as reflected by the now increasingly usual liquidity crunches at quarter-end, and which we believe is driven by the high LDRs at banks. We reiterate our view that as long as the LDRs for banks remain high and banks seek liability-side funding themselves, it is going to be a very difficult environment for life insurers. Bancassurance is clearly the most directly affected area, while agents will also be operating under a more competitive environment. As long as short-term rates remain higher than long-term ones, life insurers asset-liability matching is distorted Life insurance remains a long-term asset-liability matching business. Therefore, we think as long as short-term rates remain higher than longer-term rates in China, life insurance sales will be under pressure. This is because the longer-dated assets that life insurers use to match their long-dated liabilities do not offer sufficient yields to their policyholders relative to other asset classes. Fig. 9: Insurers P/EV vs 1-year benchmark deposit rate Fig. 1: 1-month SHIBOR minus 5-year treasury bond yield vs life insurance premium growth (x) Sector P/EV (LHS) 1 year deposit rate (RHS) Jan-4 Aug-4 Mar-5 Oct-5 May-6 Dec-6 Jul-7 Feb-8 Sep-8 Apr-9 Nov-9 Jun-1 Jan-11 Aug-11 Mar-12 Oct-12 May-13 Dec-13 (%) (%) 1m SHIBOR minus 5-year treasury bond 5 yield (LHS) life premium y-y growth (RHS) (1) (2) Jul-8 Nov-8 Mar-9 Jul-9 Nov-9 Mar-1 Jul-1 Nov-1 Mar-11 Jul-11 Nov-11 Mar-12 Jul-12 Nov-12 Mar-13 Jul-13 (%) (1) (2) Source: Bloomberg, CEIC, Nomura research Source: Bloomberg, CEIC, Nomura research 5

7 Nomura China life insurance 2 January 214 Ping An growing NBV to EV fastest within life insurers under our coverage Of the three Chinese life insurers under our coverage, Ping An demonstrates the highest VNB to EV, which means that Ping An s organic EV growth is the highest. This is important from a valuation standpoint, because the PEV will look cheaper for every year forward. This is supported by Ping An s above-peer NBV growth during 1H13. We note that the relatively high figure for PICC Life s VNB to EV is mainly because of the low base, given its shorter operating history. We also reiterate that while AIA has the highest VNB growth now relative to its Chinese peers, its organic EV growth remains the slowest. Fig. 11: China insurers VoNB as % of EV FY12/1H13 (%) Vo NB as % of EV 2 VoNB & expected return on EV as % of EV PICC Ping An CPIC Taiping China NCI Life Life Life Life Life AIA Fig. 12: China insurers VoNB growth (y-y) (%) China Life Ping An Life CPIC Life NCI 6 PICC Life Taiping Life AIA 4 2 (2) FY4 FY5 FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H13 Note: FY12 numbers for VoNB & expected return on EV as % of EV for Ping An Life, CPIC Life, PICC Life and Taiping Life. Beta analysis affirms Ping An as our top pick Our beta analysis is done with the Hang Seng Index. The one-year beta is in line with general market perceptions that brokers and insurers react more vigorously than banks relative to the index. In particular, brokers have the highest beta. However, the three-year beta tells a different story, with the three sectors having similar numbers. This suggests that on a medium-term basis, actually brokers and insurers do not offer much more leverage than banks. Within the insurers, PICC P&C clearly stands out, having the highest 1-year beta, and hence offers the most leverage to short-term index movements. Interestingly, somewhat contrary to more popular beliefs, it is the large caps of Ping An and China Life that offer higher betas than the smaller caps of New China Insurance and PICC Group. Interestingly, over a three-year basis, PICC P&C offers the lowest beta, which appears to suggest that underwriting performance may be still the key to share prices over the more medium term. We believe these findings support our views that: 1) Insurers will be particularly sensitive to investment returns this year, given the relatively high cost of liability right now. 2) Investment performance will be key to short-term share price movements of PICC P&C in the near term, given the weakening of the underwriting business. Over the longer term though, investors will still pay most attention to profitability of underwriting business, leading to de-rating of multiples. 3) Our top pick, Ping An, offers a solid fundamental business model but at the same time relatively high leverage to the index compared to China Life and CPIC. 6

8 Nomura China life insurance 2 January 214 Fig. 13: Banks, brokers and insurers sector beta for 1 year and 3 years Fig. 14: Insurers beta for 1 year and 3 years (beta) 1 year 3 years (beta) 1 year 3 years Brokers Insurers Banks. PICC P&C Ping An China Life CTIH CPIC NCI PICC Group Note: relative to Hang Seng Index Source: Bloomberg, Nomura research Source: Bloomberg, Nomura research H-A share premium the highest for insurers within financials It is interesting to note that the H-A share premium for insurers has diverged from that for banks and brokers. This suggests that H-share investors are even more optimistic for insurers versus banks and brokers compared to their A-share counterparts. Fig. 15: H-A-share premium by sectors Fig. 16: H-A-share premium by insurers Jul-6 Dec-6 May-7 Oct-7 Mar-8 Aug-8 Jan-9 Jun-9 Nov-9 Apr-1 Sep-1 Feb-11 Jul-11 Dec-11 May-12 Oct-12 Mar-13 Aug-13 Jan-14 Source: Bloomberg, Nomura research Banks Insurers Brokers China Life Ping An CPIC NCI Jan-7 Jun-7 Nov-7 Apr-8 Sep-8 Feb-9 Jul-9 Dec-9 May-1 Oct-1 Mar-11 Aug-11 Jan-12 Jun-12 Nov-12 Apr-13 Sep-13 Source: Bloomberg, Nomura research Volume growth to ensure share to financial assets is maintained In essence, with total social financing (TSF) continuing to grow at 14% y-y, the life insurance industry must maintain a similar growth rate to ensure its share of financial assets can be maintained at an acceptable level. Otherwise, the industry s influence could continue to fade, making the case for policy support from the central government increasingly difficult. 7

9 Nomura China life insurance 2 January 214 Fig. 17: y-y growth of trust balances, loan balances, total social financing and life insurance premiums 213 YTD (%) 7 6 Fig. 18: Life insurance as % of total financial assets in China 1H13 Insurers 5% Brokers 1% Trust 6% Trust Loans TSF Life insurance premium Banks 88% Note: up to Sept 213 for trust; up to Nov 213 for loan balances, TSF and life insurance premiums Source: CEIC, China Trustee Association, Nomura research Source: CEIC, CBRC, Securities Association of China, China Trustee Association, Nomura research With the industry traditionally relying heavily on savings substitute bancassurance products and the current high short-term yields, life insurers are effectively forced to grow at minimal margins or even at losses. Surrender rates will remain high as long as short-term yields remain high In our view, surrender rates will likely remain at a relatively high level given continued high short-term yields and the fact that insurers have been selling high cash value products in FY13. While we see the selling of high cash value products as slowing down the industry s structural shift towards value, nonetheless, this is a necessary step that the industry has to go through as its struggle between value and volume continues. Fig. 19: China insurers 3Q13 surrenders y-y growth Fig. 2: China insurers 9M13 surrenders rate (%) 9 (%) NCI CPIC Life China Life Ping An Life NCI China Life Note: not available for Ping An Life and CPIC Life Cashflow analysis suggests China Life and CPIC most susceptible We note that China Life has experienced a severe increase in cash paid for claims during 9M13. Its total premiums and cash balance by cash paid for claims is also the lowest within its peer group. This suggests that it is the most vulnerable to any rise in claims payments that can arise from both maturity and surrenders. 8

10 Nomura China life insurance 2 January 214 We reiterate our view that surrenders can surprise on the upside for life insurers in 214. Fig. 21: China insurers y-y growth of cash paid for claims 9M13 (%) Fig. 22: China insurers total premiums and cash balance divided by cash paid for claims 9M13 (x) China Life NCI CPIC Life Ping An Life Ping An Life NCI CPIC Life China Life Ping An deserves a premium for its higher share of renewal business Ultimately, if insurers are true to their value rather than volume/market share approach, then we believe going forward, the majority of bancassurance sales should be mainly for cashflow purposes. This is mainly to offset the still relatively high level of maturity and surrender payments in FY14/15F. Over time, the continued focus on regular premiums should mean that renewal will account for an increasing proportion of total premiums over time. As a result, we believe insurers with the highest level of renewal premiums should be valued at a premium to others, as there is less need for these insurers to sell low-margin single bancassurance products. Therefore, we believe Ping An deserves a premium to its peers. Fig. 23: China insurers single-premium bancassurance sales divided by maturity and surrender payments 1H13 (%) Note: data not available for PICC Life 46 Taiping Life CPIC Life China Life NCI Ping An Life Fig. 24: China insurers life insurance premium mix by products 1H13 (%) Others Regular-renewal Regular-new Single NCI Ping An Life CPIC Life China Life Taiping Life 9

11 Nomura China life insurance 2 January 214 Fig. 25: China insurers 1H13 FYP y-y growth Fig. 26: China insurers 1H13 renewal premiums y-y growth (%) FYP regular -agent 2 FYP single - bancassurance (%) FYP regular - bancassurance (5) China Life Ping An Life CPIC Life NCI Taiping Life Taiping Life NCI CPIC Life Ping An Life China Life Fig. 27: China insurers life insurance premium mix by channels 1H13 (%) Others Group insurance Bancassurance Agent Ping An Life CPIC LifeChina Life NCI PICC Life Taiping Life Fig. 28: China insurers bancassurance renewal as % of total premium 1H13 (%) NCI Taiping Life CPIC Life China Life Ping An Life Agency productivity still driven by case size and not number of cases Average case size growth was a key driver to first year premium growth for 1H13; however, we note this metric is more a function of disposable income and GDP growth rather than agency force efficiency improvements. We continue to point to new policies per agent per month as a critical measure for productivity and we have still yet to see a sustained improvement. In our view, for new policies per agent per month to improve, there will either need to be a structural change to the sector such as policy support for new products or significant improvement in investment returns to boost the crediting rate to policyholders. 1

12 Nomura China life insurance 2 January 214 Fig. 29: China insurers number of agents (') China Life Ping An Life CPIC Life NCI Taiping Life FY3 FY4 FY5 FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H13 Fig. 3: China insurers average new individual life policy size Fig. 31: China insurers new individual life policies per agent per month (CNY) 8, 6, 4, 2, Ping An Life CPIC Life NCI Taiping Life 7,135 7,131 7,264 5,642 4,87 5,824 6,383 4,126 3,765 4,82 3,119 3,241 2,127 2,856 3,521 1,898 1,635 1,162 1,823 2,456 2,89 2,887 FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H Ping An Life CPIC Life NCI Taiping Life FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H13 11

13 Ping An Insurance Group 2318.HK 2318 HK EQUITY: INSURANCE Only retail/mass affluent play in Financials Sector top pick FY14F is the year of divergence from life insurance peer group 214 is the year that Ping An should begin to show a valuation premium While Ping An s share price has been overshadowed by market concerns over corporate governance and shareholder changes, we believe operating fundamentals should return as the key share-price driver for 214F. We like Ping An, as unlike most peers, its surrenders will not be under pressure, it has higher organic EV and NBV growth, a high renewal premium, a high beta and undemanding-looking valuations. We think Ping An gives investors a unique exposure to China financials with its retail/mass affluent model. Migration of more profitable customers to banking and investment While we expect life insurance will remain the key value driver over the next couple of years, as the insurance business continues to migrate customers to the banking business, the income streams will diversify into more banking and investment. Both the life and non-life businesses have a relatively higher portion of affluent and mass-affluent customers, so the migration would also mean Ping An Bank absorbs more of these customers. This is very important because the affluent customers are 3x more profitable than mass-affluent, while the mass-affluent segment is 3x more profitable than mass. Undemanding valuation at 1.1x given 19% EV growth We estimate NBV to grow 1% and 11% y-y, respectively, for FY14F and FY15F, and Ping An to be the only life insurer under our coverage to report double-digit NBV growth in FY14F and FY15F. We expect EV to grow 16% and 15% y-y, respectively, in FY14F and FY15F, again the highest within our coverage. While market concerns over Chinese banks should weigh on Ping An more than peers, we see relatively limited downside for Ping An Bank (1 CH; not rated) at.8x FY14F P/B and its valuation, accounting for 12% of our sum-of-the-parts valuation. 31 Dec FY12 FY13F FY14F FY15F Currency (CNY) Actual Old New Old New Old New Net premium (mn) 221,89 248, ,584 28,29 285, , ,68 Reported net profit (mn) 2,5 29,743 29,512 35,671 34,457 4,515 39,663 Normalised net profit (mn) 2,5 29,743 29,512 35,671 34,457 4,515 39,663 FD normalised EPS FD norm. EPS growth (%) FD normalised P/E (x) 21.9 N/A 14.6 N/A 12.3 N/A 1.7 Price/EV (x) 1.1 N/A 1.3 N/A 1.1 N/A.9 Price/implied VNB (x) 1.6 N/A 5.1 N/A 1.8 N/A -1. Dividend yield (%).8 N/A 1.2 N/A 1.4 N/A 1.7 ROE (%) ROA (%) Global Markets Research 2 January 214 Rating Up from Neutral Buy Target price Increased from 6.9 HKD 8. Closing price 17 January 214 HKD Potential upside +16.4% Anchor themes Equity markets have yet to fully discount for the negative impact that rising deposit rates would have on life insurers. Additionally, we believe as long as short-term rates remain above long-term ones, the operating environment for life insurers will remain difficult. Nomura vs consensus Our FY14F earnings forecast of CNY34.5bn is 3% above market consensus. Research analysts China Insurance David Chung - NIHK [email protected] Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Source: Company data, Nomura estimates Key company data: See page 2 for company data and detailed price/index chart See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

14 Nomura Ping An Insurance Group 2 January 214 Key data on Ping An Insurance Group Profit and Loss (CNYmn) Year-end 31 Dec FY11 FY12 FY13F FY14F FY15F Gross premiums 27,82 233,94 266,39 33,33 344,366 Government charges Reinsurance ceded -1,97-12,851-14,87-17,69-19,686 Net written premium 196, ,89 251, , ,68 Change in unearned premium reserves -1,17-7,945-9,159-1,565-12,192 Net earned premium 186, , , , ,488 Claims and benefit payments -145, , ,339-24, ,959 Change in reserves Commission and DAC expenses -1,5-1, Other expenses -95,44-139,46-126,49-146,866-17,777 Underwriting surplus -55,556-93,711-68,535-76,617-86,538 Recurrent investment income 34,285 41,598 45,979 47,968 5,273 Realised and unrealised gains Investment income 34,285 41,598 45,979 47,968 5,273 Other income 51,297 84,451 7,155 84,223 1,235 Employee share expense Operating profit 3,26 32,338 47,599 55,574 63,97 Amortisation Other non-operating income Associates and JCEs Pre-tax profit 3,26 32,338 47,599 55,574 63,97 Income tax -7,444-5,588-8,225-9,63-11,54 Net profit after tax 22,582 26,75 39,374 45,971 52,916 Minority interests -3,17-6,7-9,862-11,514-13,254 Other items Preferred dividends Normalised NPAT 19,475 2,5 29,512 34,457 39,663 Extraordinary items Reported NPAT 19,475 2,5 29,512 34,457 39,663 Dividends -3,166-3,562-5,243-6,122-7,47 Transfer to retained earnings 16,39 16,488 24,269 28,335 32,616 Relative performance chart (one year) Source: ThomsonReuters, Nomura research (%) 1M 3M 12M Absolute (HKD) Absolute (USD) Relative to MSCI China Market cap (USDmn) 27,746.2 Estimated free float (%) week range (HKD) 76.5/ mth avg daily turnover (USDmn) Major shareholders (%) Charoen Pokphand Group 15.6 Shenzhen Investment Holdings 6.1 Source: Thomson Reuters, Nomura research Notes Valuation and ratio analysis Reported P/E (x) Normalised P/E (x) FD normalised P/E (x) FD normalised P/E at price target (x) Dividend yield (%) Price/book (x) Investment return (%) Recurrent investment return (%) Non-recurrent return/invt. return (%)..... Price/EV (x) Price/implied VNB (x) Loss ratio (%) Combined ratio (%) Effective tax rate (%) Dividend payout (%) ROE (%) ROA (%) ROR (%) Growth (%) Life premiums Non life premiums Net profit Normalised EPS Normalised FDEPS Source: Company data, Nomura estimates 13

15 Nomura Ping An Insurance Group 2 January 214 Balance Sheet (CNYmn) As at 31 Dec FY11 FY12 FY13F FY14F FY15F Cash and deposits 486, ,286 84,41 845, ,619 Bonds 1,124,34 1,459,616 1,526,259 1,63,829 1,693,625 Equities 222, ,89 259,28 272, ,633 Unit trusts Loans and mortgages Foreign investments Real estate Other investments 98, , , ,7 171,77 Total investments 1,931,259 2,624,232 2,744,49 2,883,51 3,44,954 Deferred acquisition costs Prepaid and unearned prem. reserves Debtors and prepayments Fixed assets Goodwill Separate account assets Other assets 354,165 22,34 445,21 69,7 96,118 Total assets 2,285,424 2,844,266 3,189,249 3,573,517 4,5,72 Insurance reserves 487, , , ,146 78,465 Catastrophe reserves Insurance protection fund Deposit and investment contracts 228,192 27, , ,684 34,523 Separate account liabilities 33,46 32,417 35,828 39,843 44,556 Provision for Unearned Premiums 42,288 5,81 6,563 71,846 84,878 Provision for Outstanding Claims Interest bearing liabilities 1,132,21 1,563,18 1,774,268 2,8,927 2,268,346 Other liabilities 19, , ,76 181, ,112 Total liabilities 2,114,82 2,634,617 2,945,482 3,291,38 3,678,881 Minority interest 4,475 5,32 58,174 67,331 77,844 Common stock 7,916 7,916 7,916 7,916 7,916 Preferred stock Retained earnings 43,546 6,43 86,38 115, ,134 Proposed dividends 3,166 3,562 5,243 6,122 7,47 Other equity 76,239 87,79 86,54 85,175 84,25 Shareholders' equity 13, , , ,86 248,347 Total liabilities and equity 2,285,424 2,844,266 3,189,249 3,573,517 4,5,72 Notes Balance sheet ratios (%) Life solvency margin Non-life solvency margin Net premiums/equity Tech. reserves/total premiums Investment portfolio mix (%) Cash and deposits Bonds Equities Unit trusts..... Loans and mortgages..... Foreign investments..... Real estate..... Other investments Per share Reported EPS (CNY) Norm EPS (CNY) Fully diluted norm EPS (CNY) DPS (CNY) BVPS (CNY) Life/LT EVPS (CNY) Life/LT VNBPS (CNY) Value of non-life bus. PS (CNY)..... Source: Company data, Nomura estimates 14

16 Nomura Ping An Insurance Group 2 January 214 One customer, one account and multiple products We are fans of Ping An s clear strategy to provide a full spectrum of financial products to its customers. While Ping An, like its peers, is suffering from slower growth at the moment, we believe the key difference is that Ping An s growth path is much more clear and sustainable in the medium term. Most of its peers are still in the very early reform stages and are selling high cash value products knowing that there is a high possibility of surrender in one year's time. In the end, this loses customers in the process and does not create much shareholder value. In our view, Ping An s profit contribution should still be dominated by the insurance business (both life and non-life) over the next couple of years. We think this is also where the misperception is, as investors focus too much on its life valuation, and hence growth. It is increasingly clear that Ping An s more important growth driver is probably not the insurance business but the overall cross-selling process from insurance to banking and investment. Fig. 32: Ping An profit by segment FY12 & 1H13 (%) FY12 1H13 Others Trust Securities Banking P&C insurance Life insurance Over the next few years, as the insurance business continues to migrate customers to the banking business, we expect the income streams will diversify into more banking and investment. This, we believe, is important because it implies that Ping An can afford to have a larger agency force as this agency force helps it distribute not only insurance but also other financial products. For example, we understand that income from cross-selling accounted for 13% of total income for agents in 213. As the chart below indicates, the life and non-life businesses have a relatively higher portion of affluent and mass-affluent customers so the migration would also mean Ping An Bank absorbs more of these customers, in our view. 15

17 Nomura Ping An Insurance Group 2 January 214 Fig. 33: Ping An's retail customer structures (%) Affluent Mass-affluent Mass Ping An Group PAB Ping An Life Ping An P&C Source: Ping An, Nomura research Fig. 34: Ping An's profit contribution (%) Investment Banking Insurance 212 in 3-5 years in 6-8 years Source: Ping An, Nomura research According to Ping An, it is important to have more affluent and mass affluent customers because the affluent customers are three-times more profitable than mass-affluent while the mass-affluent customers are 3-times more profitable than mass. In particular, ~7% of the affluent and mass-affluent customers of Ping An are of a younger age group of years relative to 57% for the mass market. This implies that these customers still have time to grow their wealth and they can remain with Ping An for a longer period of time. Fig. 35: Ping An retail customer age distribution by wealth level (%) Affluent Mass affluent Mass Source: Ping An, Nomura research > 65 years old years old years old years old years old < 26 years old Fig. 36: Ping An average profit contribution per customer 3 times 3 times Affluent Mass affluent Mass Source: Ping An, Nomura research We remain a fan of Ping An s goal to become the primary wealth manager for affluent and mass-affluent customers, which is in sharp contrast to some of its peers exposure to the mass market and singular life insurance products. We believe Ping An can achieve its goal by offering a variety of financial products through its subsidiaries. 16

18 Nomura Ping An Insurance Group 2 January 214 Fig. 37: China's personal investable assets (CNY trn) 9 Cash & deposits 8 Investment properties 7 Capital market 6 5 Other investments CAGR Other investments +31% Capital market +23% Investment properties +29% Cash & deposits +16% Source: Ping An, Nomura research Fig. 38: Ping An financial summary P&L F 214F 215F F 214F 215F Amount (CNYmn) y-y change (%) Gross written premiums 159,384 27,82 233,94 266,39 33,33 344, Less: premium ceded to reinsurers (8,181) (1,97) (12,851) (14,87) (17,69) (19,686) Net written premiums 151,23 196, ,89 251, , , Net change in unearned premium reserves (1,79) (1,17) (7,945) (9,159) (1,565) (12,192) 1 (22) Net premiums earned 141, , , , , , Reinsurance commission income 2,616 3,656 4,529 5,661 7,77 8, Net interest income from banking 5,934 18,882 34,51 36,417 4,779 45, Fees and commission income 5,543 8,614 1,891 1,281 14,53 17, (6) Net investment income 31,83 29,265 27,378 45,979 47,968 5,273 (6) (6) Others 6,117 4,733 8,399 17,796 22,314 27,98 (23) Total revenue 192, , , ,559 47, , Claims and policyholders' benefits (115,77) (145,764) (165,994) (184,339) (24,896) (227,959) Insurance related handling charges and commission (14,545) (17,767) (2,437) (24,43) (27,749) (31,521) Fees & commission expense of non-insurance operations (69) (1,5) (1,455) (212) (254) (29) (85) 2 14 Impairment losses (626) (1,74) (3,48) (5,35) (6,583) (8,28) General and administrative expenses (34,385) (5,575) (68,477) (73,258) (84,586) (97,78) Finance costs (913) (1,254) (1,758) (1,934) (2,127) (2,34) Other operating expenses (3,915) (3,672) (5,335) (21,463) (25,82) (31,18) (6) Total expenses (17,7) (221,786) (266,54) (31,96) (352,16) (399,26) Profit before tax 22,347 3,26 32,338 47,599 55,574 63, Income tax expense (4,49) (7,444) (5,588) (8,225) (9,63) (11,54) 69 (25) Net profit 17,938 22,582 26,75 39,374 45,971 52, Non-controlling interests 627 3,17 6,7 9,862 11,514 13, Profit attributable to owners 17,311 19,475 2,5 29,512 34,457 39, Source: Nomura estimates Valuation methodology Following the change in analyst coverage, our target price of HKD8 is based on a sumof-the-parts (SOTP) valuation. For the life business, we apply our target new business multiple of 5.x to the FY15F new business value and then add FY14F embedded value. We value Ping An s P&C business by applying 1x P/E to its FY14F NPAT, and its securities and trust operations by applying 1x P/E to its FY14F NPAT, respectively. We incorporate PAB into our valuation of Ping An by applying a target P/BV multiple of.8x to our FY14F BV forecast. The implied target P/EV is 1.3x, vs the historical average of 1.9x and current level of 1.1x. The benchmark index for this stock is MSCI China. Investment risks Key downside risks include poorer-than-expected execution of the financial conglomerate model, integration with PAB and returns from the A-share market, which would affect sentiment to insurers in general, in our view. Key upside risks are better and earlier-than-expected synergies from the integration of PAB. 17

19 China Life Insurance 2628.HK 2628 HK EQUITY: INSURANCE Reform challenged by rising deposit rates Market yet to fully discount impact of rising deposit rates on sales and surrenders Downside risks as life insurers not ready for new environment We are adamant that the market has yet to fully appreciate what rising deposit rates would mean for life insurers. In fact, we are not sure if the managements at most life insurers themselves are ready for such an environment. While we appreciate China Life s management s commitment to the strategic change from volume to value, we think the transparency is low for sales growth and surrenders. We are now expecting low single digit VNB growth for FY14/15F, but we feel the risk is more to the downside than upside. We cut our TP from HKD21 to HKD 2 and lower our rating from Neutral to Reduce. More low-margin products necessary to maintain cashflow We expect another ~CNY6bn in maturity payments in FY14F relative to the ~CNY1bn in FY13F, while surrenders will also likely reach ~CNY2bn. Hence, our current expectation is that single-premium bancassurance sales could still be at least CNY6bn for FY14F, or around 86% of the FY13F level, to ensure cashflow is balanced. This should drop off to CNY3bn by FY15F and CNY1bn by FY16F. We note these bancassurance products will need to have cash value after one year of 13-4% of the initial premium (equivalent the yield of 1-year time deposits) for the products to be sold. Assuming these products were sold at 3-4% commission rates and life insurers earn about 4-5% yields, then in general, China Life is still making a 2-3% loss in the spread. Recurring premiums will replace bancassurance, but only very gradually Assuming first year regular premiums grow by 4-1% during FY14/15F, supporting renewal premiums growth of 8-9%, then we expect total premiums to reach CNY353bn in FY15F, implying a market share of ~3%, which should be largely in line with management s one-third target. 31 Dec FY12 FY13F FY14F FY15F Currency (CNY) Actual Old New Old New Old New Net premium (mn) 322, , , , ,6 355, ,884 Reported net profit (mn) 11,61 28,576 28,17 33,216 33,9 42,297 38,529 Normalised net profit (mn) 11,61 28,576 28,17 33,216 33,9 42,297 38,529 FD normalised EPS 39.13c c FD norm. EPS growth (%) FD normalised P/E (x) 46.6 N/A 18. N/A 15.1 N/A 12.9 Price/EV (x) 1.5 N/A 1.3 N/A 1.1 N/A 1. Price/implied VNB (x) 8.4 N/A 5.2 N/A 2.8 N/A.6 Dividend yield (%).8 N/A 2. N/A 2.4 N/A 2.8 ROE (%) ROA (%) Global Markets Research 2 January 214 Rating Down from Neutral Reduce Target price Reduced from 21. HKD 2. Closing price 17 January 214 HKD Potential downside -11.7% Anchor themes Equity markets have yet to fully discount for the negative impact that rising deposit rates would have on life insurers. Additionally, we believe as long as short-term rates remain above long-term ones, the operating environment for life insurers will remain difficult. Nomura vs consensus Our FY14F earnings forecast of CNY33bn is 8% lower than consensus. Research analysts China Insurance David Chung - NIHK [email protected] Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Source: Company data, Nomura estimates Key company data: See page 2 for company data and detailed price/index chart See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

20 Nomura China Life Insurance 2 January 214 Key data on China Life Insurance Profit and Loss (CNYmn) Year-end 31 Dec FY11 FY12 FY13F FY14F FY15F Gross premiums 318, ,742 34,8 354, ,34 Government charges Reinsurance ceded Net written premium 318,2 322, , ,6 352,884 Change in unearned premium reserves Net earned premium 318, , , ,85 352,63 Claims and benefit payments -181, ,99-192,48-187, ,293 Change in reserves Commission and DAC expenses Other expenses -171,2-178,564-26,818-23, ,997 Underwriting surplus -34,323-41,428-59,435-63,999-67,66 Recurrent investment income 6,722 73,243 88,23 98,748 19,4 Realised and unrealised gains -1,871-27,189 Investment income 49,851 46,54 88,23 98,748 19,4 Other income Employee share expense Operating profit 15,528 4,626 28,769 34,749 41,38 Amortisation Other non-operating income 2,772 3,35 3,47 3,644 3,826 Associates and JCEs 2,213 3,37 3,189 3,348 3,516 Pre-tax profit 2,513 1,968 35,428 41,741 48,721 Income tax -2, ,73-7,929-9,255 Net profit after tax 18,491 11,272 28,698 33,812 39,466 Minority interests Other items Preferred dividends Normalised NPAT 18,331 11,61 28,17 33,9 38,529 Extraordinary items Reported NPAT 18,331 11,61 28,17 33,9 38,529 Dividends -6,51-3,957-1,23-11,89-13,784 Transfer to retained earnings 11,83 7,14 17,994 21,2 24,745 Relative performance chart (one year) Source: ThomsonReuters, Nomura research (%) 1M 3M 12M Absolute (HKD) Absolute (USD) Relative to MSCI China Market cap (USDmn) 21,733.7 Estimated free float (%) week range (HKD) 27/17 3-mth avg daily turnover (USDmn) Major shareholders (%) CLIC 68.4 Credit Suisse 3.4 Source: Thomson Reuters, Nomura research Notes Valuation and ratio analysis Reported P/E (x) Normalised P/E (x) FD normalised P/E (x) FD normalised P/E at price target (x) Dividend yield (%) Price/book (x) Investment return (%) Recurrent investment return (%) Non-recurrent return/invt. return (%) Price/EV (x) Price/implied VNB (x) Loss ratio (%) Combined ratio (%) Effective tax rate (%) Dividend payout (%) ROE (%) ROA (%) ROR (%) Growth (%) Life premiums Non life premiums Net profit Normalised EPS Normalised FDEPS Source: Company data, Nomura estimates 19

21 Nomura China Life Insurance 2 January 214 Balance Sheet (CNYmn) As at 31 Dec FY11 FY12 FY13F FY14F FY15F Cash and deposits 576,778 71, ,85 883, ,488 Bonds 666, ,98 928,698 1,29,49 1,125,24 Equities 18,61 161,296 18,891 2,57 219,173 Unit trusts Loans and mortgages Foreign investments Real estate Other investments 7,897 9,912 11, ,13 123,533 Total investments 1,494,969 1,79,838 2,8,395 2,226,191 2,433,435 Deferred acquisition costs Prepaid and unearned prem. reserves Debtors and prepayments Fixed assets Goodwill Separate account assets Other assets 88,938 18,78 123,718 13,692 14,69 Total assets 1,583,97 1,898,916 2,132,113 2,356,884 2,574,44 Insurance reserves 1,193,675 1,378,582 1,57,873 1,758,636 1,93,417 Catastrophe reserves Insurance protection fund Deposit and investment contracts 69,797 66,639 64,669 61,157 58,434 Separate account liabilities Provision for Unearned Premiums 5,698 5,955 6,425 7,258 8,22 Provision for Outstanding Claims Interest bearing liabilities 29,99 67,981 67,983 67,983 67,983 Other liabilities 91, , ,15 2, ,352 Total liabilities 1,39,519 1,675,815 1,889,271 2,96,158 2,292,565 Minority interest 1,858 2,16 2,117 2,223 2,334 Common stock 28,265 28,265 28,265 28,265 28,265 Preferred stock Retained earnings 79,894 8,392 94,428 15,65 118,542 Proposed dividends 6,51 3,957 1,23 11,89 13,784 Other equity 76,87 18,471 18,8 112, ,555 Shareholders' equity 191,53 221,85 24, ,53 279,145 Total liabilities and equity 1,583,97 1,898,916 2,132,113 2,356,884 2,574,44 Notes Balance sheet ratios (%) Life solvency margin Non-life solvency margin Net premiums/equity Tech. reserves/total premiums Investment portfolio mix (%) Cash and deposits Bonds Equities Unit trusts..... Loans and mortgages..... Foreign investments..... Real estate..... Other investments Per share Reported EPS (CNY) 64.85c 39.13c 99.12c Norm EPS (CNY) 64.85c 39.13c 99.12c Fully diluted norm EPS (CNY) 64.85c 39.13c 99.12c DPS (CNY) BVPS (CNY) Life/LT EVPS (CNY) Life/LT VNBPS (CNY) Value of non-life bus. PS (CNY)..... Source: Company data, Nomura estimates 2

22 Nomura China Life Insurance 2 January 214 Fig. 39: China Life 12m forward P/EV (x) P/EV Avg. -1SD +1SD Fig. 4: China insurers 9M13 surrenders rate (%) Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 NCI China Life Source: Bloomberg, Nomura research Note: not available for Ping An Life and CPIC Life Fig. 41: China insurers y-y growth of cash paid for claims 9M13 (%) China Life NCI CPIC Life Ping An Life Fig. 42: China insurers total premium and cash balance divided by cash paid for claims 9M13 (x) Ping An Life NCI CPIC Life China Life Fig. 43: China insurers 1H13 FYP y-y growth (%) FYP regular -agent 2 FYP single - bancassurance FYP regular - bancassurance 15 Fig. 44: China insurers 1H13 renewal premiums y-y growth (%) (5) China Life Ping An Life CPIC Life NCI Taiping Life Taiping Life NCI CPIC Life Ping An Life China Life 21

23 Nomura China Life Insurance 2 January 214 Fig. 45: China Life financial summary P&L F 214F 215F F 214F 215F Amount (CNYmn) y-y change (%) Gross written premiums 318, , ,742 34,8 354, , () Less: premium ceded to reinsurers (177) (232) (384) (45) (422) (42) () Net written premiums 318,52 318,2 322, , ,6 352,884 () () Net change in unearned premium reserves (232) (244) (255) (254) 611 na 5 4 () Net premiums earned 318,88 318, , , ,85 352, () Net ivestment income 64,993 49,851 46,54 88,23 98,748 19,4 (23) (8) Other income 2,757 2,772 3,35 3,47 3,644 3, Total revenue 385,838 37, , ,14 456, ,496 (4) Life Insurance benefits, claims and expenses (71,237) (11,349) (17,674) (124,48) (141,778) (158,721) Accident and Health Claims and adjustment expenses (8,74) (7,789) (7,898) (8,522) (9,626) (1,878) (11) Increases in future life policyholder benefits (199,655) (181,579) (184,99) (192,48) (187,333) (171,293) (9) 2 4 (2) (9) Interest credited to policyholder contract deposits (1,95) (2,31) (2,32) (1,97) (3,512) (2,723) 4 (3) 78 (22) Policy dividends and participation in profits (13,224) (6,125) (3,435) (4,137) (4,631) (5,114) (54) (44) Underwriting and policy acquisition costs (27,256) (27,434) (27,754) (29,245) (3,483) (3,382) () Administrative expenses (2,285) (21,549) (23,283) (31,1) (32,911) (33,581) Other operating expenses (3,351) (3,275) (3,34) (3,37) (3,437) (3,56) (2) Interest expense (34) (873) (2,575) (3,424) (3,424) (3,424) Statutory insurance levy (599) (595) (69) (642) (669) (667) (1) () Total expenses (346,61) (352,599) (363,554) (398,865) (417,84) (42,29) Share of associates 1,771 2,213 3,37 3,189 3,348 3, Profit before tax 41,8 2,513 1,968 35,428 41,741 48,721 (5) (47) Income tax expense (7,197) (2,22) 34 (6,73) (7,929) (9,255) (72) na na Net profit 33,811 18,491 11,272 28,698 33,812 39,466 (45) (39) Non-controlling interests (14) Profit attributable to owners 33,626 18,331 11,61 28,17 33,9 38,529 (45) (4) Source: Nomura estimates Valuation methodology Following the change in analyst coverage, our target price of HKD2 is premised on a target new business (NB) multiple of 1.x. We apply the target NB multiple to China Life s FY15F new business value and add its FY14F embedded value. The implied target P/EV is 1.x, vs the historical average of 2.x and the current level of 1.1x. The benchmark index for this stock is MSCI China. Investment risks Key upside risks include: 1) stronger-than-expected returns from the A-share market; and 2) an earlier-than-expected pick-up in momentum in the life insurance industry. Key downside risks include: 1) poor returns from the A-share market affecting sentiment to insurers in general; and 2) intense competition leading to a continued squeeze in NB margins for life insurers, especially China Life, which hopes to recapture market share. 22

24 China Pacific Insurance 261.HK 261 HK EQUITY: INSURANCE Lack of catalysts near term Investors usual pick by process of elimination, but unexciting at best in the near term Non-life and bancassurance drag to performance Given our negative sector outlook for the non-life business (online competition and motor pricing deregulation), we downgrade CPIC to Reduce with a revised TP of HKD26. According to our calculation, the non-life business accounts for 17% of CPIC s valuation if we apply a 1x P/E multiple, which is similar to that of PICC P&C. While CPIC demonstrates similar EV and NBV growth to Ping An, it is much more geared to bancassurance and, hence, it is also suffering from high level of surrenders. This means that it will also likely be under pressure to sell low-margin bancassurance products to cover surrenders, especially given our view that surrenders could surprise on the upside when deposit rates further deregulate. Prefer Ping An given similar valuation at 1.1x FY14F PEV Our calculation indicates that the total premium and cash divided by cash paid for claims for CPIC is similar to that of China Life at ~2x, relative to Ping An s 5x. This means CPIC is more susceptible to rising surrenders than Ping An and must either sell more low-margin bancassurance or retain more cash on hand (hence affecting investment yields) to maintain its cash level. According to our calculation, CPIC also has a lower beta than Ping An and China Life and, hence, may not be suitable for investors seeking leverage to the index. We estimate NBV to grow by 5% in both FY14F and FY15F, and EV to grow by 13% in FY14F and 12% in FY15F. We see limited catalysts in the near term. Global Markets Research 2 January 214 Rating Down from Neutral Reduce Target price Reduced from 28. HKD 26. Closing price 17 January 214 HKD 28.2 Potential downside -7.8% Anchor themes Equity markets have yet to fully discount for the negative impact that rising deposit rates would have on life insurers. Additionally, we believe as long as short-term rates remain above long-term ones, the operating environment for life insurers will remain difficult. Nomura vs consensus Our FY14F earnings forecast of CNY11.9bn is 2% below market consensus. Research analysts China Insurance David Chung - NIHK [email protected] Dec FY12 FY13F FY14F FY15F Currency (CNY) Actual Old New Old New Old New Net premium (mn) 151, , , , , ,254 26,632 Reported net profit (mn) 5,77 8,716 1,226 12,51 11,934 13,65 14,11 Normalised net profit (mn) 5,77 8,716 1,226 12,51 11,934 13,65 14,11 FD normalised EPS 58.62c 96.18c FD norm. EPS growth (%) FD normalised P/E (x) 38.7 N/A 19.7 N/A 16.6 N/A 14.1 Price/EV (x) 1.5 N/A 1.3 N/A 1.1 N/A 1. Price/implied VNB (x) 9.4 N/A 6. N/A 3.1 N/A.5 Dividend yield (%) 1.5 N/A 1.8 N/A 2.1 N/A 2.5 ROE (%) ROA (%) Source: Company data, Nomura estimates Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Key company data: See page 2 for company data and detailed price/index chart See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

25 Nomura China Pacific Insurance 2 January 214 Key data on China Pacific Insurance Profit and Loss (CNYmn) Year-end 31 Dec FY11 FY12 FY13F FY14F FY15F Gross premiums 154, , ,446 2, ,968 Government charges Reinsurance ceded -13,384-11,795-13,613-15,788-18,336 Net written premium 141, , , ,797 26,632 Change in unearned premium reserves -4,336-3,594-4,181-4,876-5,692 Net earned premium 137, , , ,921 2,94 Claims and benefit payments Change in reserves -56,63-58,51-66,232-67,935-69,587 Commission and DAC expenses Other expenses -89,55-12, , ,95-157,2 Underwriting surplus -8,375-13,25-21,84-23,919-25,667 Recurrent investment income 21,38 26,878 32,832 36,92 41,2 Realised and unrealised gains Investment income 21,38 26,878 32,832 36,92 41,2 Other income -3,11-7,56 1,321 1,387 1,456 Employee share expense Operating profit 9,94 6,113 12,312 14,37 16,989 Amortisation Other non-operating income 495 Associates and JCEs Pre-tax profit 1,399 6,113 12,312 14,37 16,989 Income tax -2, ,98-2,311-2,732 Net profit after tax 8,393 5,13 1,332 12,59 14,257 Minority interests Other items Preferred dividends Normalised NPAT 8,313 5,77 1,226 11,934 14,11 Extraordinary items Reported NPAT 8,313 5,77 1,226 11,934 14,11 Dividends -3,1-3,172-3,579-4,177-4,938 Transfer to retained earnings 5,33 1,95 6,647 7,757 9,171 Relative performance chart (one year) Source: ThomsonReuters, Nomura research (%) 1M 3M 12M Absolute (HKD) Absolute (USD) Relative to MSCI HK Market cap (USDmn) 1,92.1 Estimated free float (%) week range (HKD) 33.5/ mth avg daily turnover (USDmn) Major shareholders (%) Fortune Investment 14.2 Shenergy Group 13.7 Source: Thomson Reuters, Nomura research Notes Valuation and ratio analysis Reported P/E (x) Normalised P/E (x) FD normalised P/E (x) FD normalised P/E at price target (x) Dividend yield (%) Price/book (x) Investment return (%) Recurrent investment return (%) Non-recurrent return/invt. return (%)..... Price/EV (x) Price/implied VNB (x) Loss ratio (%) Combined ratio (%) Effective tax rate (%) Dividend payout (%) ROE (%) ROA (%) ROR (%) Growth (%) Life premiums Non life premiums Net profit Normalised EPS Normalised FDEPS Source: Company data, Nomura estimates 24

26 Nomura China Pacific Insurance 2 January 214 Balance Sheet (CNYmn) As at 31 Dec FY11 FY12 FY13F FY14F FY15F Cash and deposits 155, ,61 217, , ,83 Bonds 293, , ,62 439, ,452 Equities 52,18 61,39 68,693 76,69 85,73 Unit trusts Loans and mortgages Foreign investments Real estate Other investments 6,393 6,179 6,954 7,764 8,612 Total investments 58,24 61, , ,122 85,967 Deferred acquisition costs Prepaid and unearned prem. reserves Debtors and prepayments Fixed assets 7,833 9,364 Goodwill Separate account assets Other assets 53,577 6,612 84,142 97, ,29 Total assets 57, ,52 771,27 864, ,996 Insurance reserves 374, , , ,69 665,52 Catastrophe reserves Insurance protection fund Deposit and investment contracts 47,182 41,754 45,321 49,34 53,835 Separate account liabilities Provision for Unearned Premiums Provision for Outstanding Claims Interest bearing liabilities 8, 15,5 15,688 15,688 15,688 Other liabilities 62,444 87,792 93,333 97,812 12,86 Total liabilities 492, , , ,99 837,831 Minority interest 1,259 1,392 1,53 1,633 1,786 Common stock 8,6 9,62 9,62 9,62 9,62 Preferred stock Retained earnings 17,993 19,596 26,243 34, 43,171 Proposed dividends 3,1 3,172 3,579 4,177 4,938 Other equity 47,193 64,347 64,963 65,558 66,28 Shareholders' equity 76,796 96,177 13, , ,379 Total liabilities and equity 57, ,52 771,27 864, ,996 Notes Balance sheet ratios (%) Life solvency margin na na na Non-life solvency margin Net premiums/equity Tech. reserves/total premiums Investment portfolio mix (%) Cash and deposits Bonds Equities Unit trusts..... Loans and mortgages..... Foreign investments..... Real estate..... Other investments Per share Reported EPS (CNY) 96.66c 58.62c Norm EPS (CNY) 96.66c 58.62c Fully diluted norm EPS (CNY) 96.66c 58.62c DPS (CNY) BVPS (CNY) Life/LT EVPS (CNY) Life/LT VNBPS (CNY) Value of non-life bus. PS (CNY)..... Source: Company data, Nomura estimates 25

27 Nomura China Pacific Insurance 2 January 214 Fig. 46: CPIC 12m forward P/EV Fig. 47: China insurers 3Q13 surrenders y-y growth (x) P/EV Avg. -1SD +1SD Jan-11 Mar-11 May-11 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13 Jan-14 (%) NCI CPIC Life China Life Ping An Life Source: Bloomberg, Nomura research Fig. 48: China insurers total premium and cash balance divided by cash paid for claims 9M13 (x) Ping An Life NCI CPIC Life China Life Fig. 49: China insurers single premium bancassurance sales divided by maturity and surrender payments 9M13 (%) Taiping Life CPIC Life China Life NCI Ping An Life Fig. 5: China insurers life insurance premium mix by channels 1H13 (%) Others Group insurance Bancassurance Agent Ping An Life CPIC LifeChina Life NCI PICC Life Taiping Life Fig. 51: China insurers number of agents China Life Ping An Life (') CPIC Life NCI Taiping Life FY3 FY4 FY5 FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H13 26

28 Nomura China Pacific Insurance 2 January 214 Fig. 52: China insurers average new individual life policy size Fig. 53: China insurers new individual life policies per agent per month (CNY) 8, 6, 4, 2, Ping An Life CPIC Life NCI Taiping Life 7,135 7,131 7,264 5,642 4,87 5,824 6,383 4,126 3,765 4,82 3,119 3,241 2,127 2,856 3,521 1,898 1,635 1,162 1,823 2,456 2,89 2,887 FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H Ping An Life CPIC Life NCI Taiping Life FY6 FY7 FY8 FY9 FY1 FY11 FY12 1H13 Fig. 54: CPIC financial summary P&L F 214F 215F F 214F 215F Amount (CNYmn) y-y change (%) Gross written premiums 139, , , ,446 2, , Less: premium ceded to reinsurers (13,422) (13,384) (11,795) (13,613) (15,788) (18,336) () (12) Net written premiums 126, , , , ,797 26, Net change in unearned premium reserves (6,382) (4,336) (3,594) (4,181) (4,876) (5,692) (32) (17) Net premiums earned 119, , , , ,921 2, Net ivestment income 2,657 16,392 18,6 32,832 36,92 41,2 (21) Other income 919 1,887 1,258 1,321 1,387 1, (33) Total revenue 141, , , ,84 218,21 243, Life insurance death and other benefits paid (17,18) (21,58) (2,596) (24,374) (28,564) (32,862) 26 (4) Claims incurred (2,829) (28,1) (35,815) (42,375) (49,942) (58,897) Change in insurance contract reserves (59,241) (56,63) (58,51) (66,232) (67,935) (69,587) (5) Policyholder dividends (3,399) (3,87) (3,95) (4,77) (5,361) (5,986) Finance costs (373) (848) (2,288) (2,631) (3,26) (3,48) General and administrative expenses (29,785) (35,377) (39,939) (43,11) (49,11) (55,795) Total expenses (13,645) (145,613) (161,44) (183,492) (23,84) (226,67) Non-operating income/expenses (12) 495 na na na na na Profit before tax 1,67 1,399 6,113 12,312 14,37 16,989 (3) (41) Income tax expense (2,5) (2,6) (983) (1,98) (2,311) (2,732) (51) Net profit 8,665 8,393 5,13 1,332 12,59 14,257 (3) (39) Non-controlling interests (26) (34) Profit attributable to owners 8,557 8,313 5,77 1,226 11,934 14,11 (3) (39) Source: Nomura estimates Valuation methodology Following the change in analyst coverage, our revised target price of HKD26 is premised on a sum-of-the-parts (SOTP) valuation. For the life business, we apply our target NB multiple of 1.x to CPIC Life s FY15F new business value and add its FY14F embedded value. We value CPIC s P&C business by applying 1x P/E to its FY14F NPAT and add the free capital available. The implied target P/EV is 1.x, vs the historical average of 1.5x and the current level of 1.1x. The benchmark index for this stock is MSCI China. Investment risks Key upside risks: 1) sales of bancassurance products supporting higher VoNB growth; and 2) stronger-than-expected returns from the A-share market, which would likely boost general sentiment toward insurers. 27

29 AIA 1299.HK 1299 HK EQUITY: INSURANCE Accumulate, especially before the results Valuation premium deserved, given management execution and growth profile Investments and currency to drag on book value growth for FY13 We note that the MSCI Asia Ex Japan returned 5% during AIA s calendar year FY13 (2% in 2H13), relative to 16% in FY12. Our assumptions for local equities returns are 7-1% in the EV. We estimate there will likely be negative variance of around USD35mn, or a 1% impact, for FY13. On currency, the USD has strengthened against most Asian currencies, for example, USD to Thai Baht strengthened by ~4% during FY13, with most of the gains in 2H13. We estimate the impact to be around USD6mn, or 2% of book value. The US 1y bond yield rose by 1bp in FY13, or 6bp during 2H13. We estimate marked-to-market losses of around USD2.2bn in 213, or around 8% of book value. Therefore, we see likely downside risks to our current book value estimate. Structural growth profile so the key is getting the entry timing right In general, we remain positive on the growth profile of AIA, noting that each of its geographic markets delivered double-digit NBV growth in 3Q13. Its recent announcement of a bancassurance partnership with Citibank should also strengthen its growth profile further we think; however, it is difficult to quantify the actual impact at this stage. We reaffirm Buy and advise to accumulate the stock, especially towards end-january and early-february where AIA has a tendency to surprise to the upside on its results announcement (late- February). Global Markets Research 2 January 214 Rating Remains Buy Target price Remains HKD 41. Closing price 17 January 214 HKD Potential upside +5.8% Anchor themes Equity markets have yet to fully discount for the negative impact that rising deposit rates would have on life insurers. Additionally, we believe as long as short-term rates remain above long-term ones, the operating environment for life insurers will remain difficult. Nomura vs consensus Our FY14F NPAT forecast of USD3,649mn is 5% higher than market concensus. Research analysts China Insurance David Chung - NIHK [email protected] Nov FY12 FY13F FY14F FY15F Currency (USD) Actual Old New Old New Old New Net premium (mn) 13,54 13,837 13,837 14,86 14,86 15,842 15,842 Reported net profit (mn) 3,19 3,171 3,171 3,649 3,649 3,967 3,967 Normalised net profit (mn) 3,19 3,171 3,171 3,649 3,649 3,967 3,967 FD normalised EPS 25.7c 26.33c 26.33c 3.3c 3.3c 32.94c 32.94c FD norm. EPS growth (%) FD normalised P/E (x) 19.9 N/A 19. N/A 16.5 N/A 15.2 Price/EV (x) 1.9 N/A 1.8 N/A 1.6 N/A 1.4 Price/implied VNB (x) 24.3 N/A 18. N/A 12.7 N/A 8.7 Dividend yield (%) 1. N/A 1.1 N/A 1.2 N/A 1.3 ROE (%) ROA (%) Source: Company data, Nomura estimates Lucy Feng - NIHK [email protected] Ben Huang - NIHK [email protected] Key company data: See page 2 for company data and detailed price/index chart See Appendix A-1 for analyst certification, important disclosures and the status of non-us analysts.

30 Nomura AIA 2 January 214 Key data on AIA Profit and Loss (USDmn) Year-end 3 Nov FY11 FY12 FY13F FY14F FY15F Gross premiums 14,442 15,36 16,282 17,421 18,641 Government charges Reinsurance ceded -2,141-2,36-2,444-2,615-2,799 Net written premium 12,31 13,54 13,837 14,86 15,842 Change in unearned premium reserves Net earned premium 12,31 13,54 13,837 14,86 15,842 Claims and benefit payments -9,72-13,374-14,492-15,361-16,437 Change in reserves Commission and DAC expenses -2,92-2,981-3,9-3,291-3,54 Other expenses Underwriting surplus 183-3,58-3,879-3,98-4,233 Recurrent investment income 4,15 4,463 5,517 5,998 6,549 Realised and unrealised gains -2,177 2,743 2,229 2,435 2,527 Investment income 1,973 7,26 7,745 8,433 9,76 Other income Employee share expense Operating profit 2,156 3,698 3,867 4,453 4,843 Amortisation Other non-operating income Associates and JCEs Pre-tax profit 2,168 3,714 3,882 4,468 4,858 Income tax Net profit after tax 1,68 3,29 3,181 3,659 3,977 Minority interests Other items Preferred dividends Normalised NPAT 1,6 3,19 3,171 3,649 3,967 Extraordinary items Reported NPAT 1,6 3,19 3,171 3,649 3,967 Dividends Transfer to retained earnings 1,7 2,445 2,528 2,929 3,16 Relative performance chart (one year) Source: ThomsonReuters, Nomura research (%) 1M 3M 12M Absolute (HKD) Absolute (USD) Relative to MSCI HK Market cap (USDmn) 6,181.9 Estimated free float (%) 52-week range (HKD) 4.45/ mth avg daily turnover (USDmn) 1.34 Major shareholders (%) JP MORGAN CHASE & CO 1.7 BLACKROCK INC 6.3 Source: Thomson Reuters, Nomura research Notes Valuation and ratio analysis Reported P/E (x) Normalised P/E (x) FD normalised P/E (x) FD normalised P/E at price target (x) Dividend yield (%) Price/book (x) Investment return (%) Recurrent investment return (%) Non-recurrent return/invt. return (%) Price/EV (x) Price/implied VNB (x) Loss ratio (%) Combined ratio (%) Effective tax rate (%) Dividend payout (%) ROE (%) ROA (%) ROR (%) Growth (%) Life premiums Non life premiums na na na na Net profit Normalised EPS Normalised FDEPS Source: Company data, Nomura estimates 29

31 Nomura AIA 2 January 214 Balance Sheet (USDmn) As at 3 Nov FY11 FY12 FY13F FY14F FY15F Cash and deposits 3,515 2,213 2,44 2,626 2,826 Bonds 65,561 78,818 86,894 93,536 1,644 Equities 7,165 9,19 1,132 1,96 11,735 Unit trusts Loans and mortgages 4,422 6,35 7,1 7,536 8,18 Foreign investments Real estate 896 1,35 1,87 1,141 1,198 Other investments Total investments 82,284 98,24 18,36 116, ,444 Deferred acquisition costs 12,818 14,161 14,869 15,613 16,393 Prepaid and unearned prem. reserves Debtors and prepayments Fixed assets Goodwill Separate account assets 1,866 14,376 11,57 11,111 11,168 Other assets 7,858 6,978 8,652 1,485 12,55 Total assets 114, , ,61 154, ,32 Insurance reserves 78,752 9,574 96,8 12,729 19,92 Catastrophe reserves Insurance protection fund Deposit and investment contracts 8,36 8,865 9,486 1,15 1,86 Separate account liabilities Provision for Unearned Premiums Provision for Outstanding Claims Interest bearing liabilities ,2 Other liabilities 5,375 7,46 7,83 8,292 8,795 Total liabilities 93,46 17, , ,97 13,595 Minority interest Common stock 12,44 12,44 12,44 12,44 12,44 Preferred stock Retained earnings 5,167 7,697 1,34 13,32 16,576 Proposed dividends Other equity 4,12 6,956 6,956 6,956 6,956 Shareholders' equity 21,313 26,697 29,34 32,32 35,576 Total liabilities and equity 114, , ,61 154, ,32 Notes Balance sheet ratios (%) Life solvency margin Non-life solvency margin Net premiums/equity Tech. reserves/total premiums Investment portfolio mix (%) Cash and deposits Bonds Equities Unit trusts..... Loans and mortgages Foreign investments..... Real estate Other investments Per share Reported EPS (USD) 13.28c 25.7c 26.33c 3.3c 32.94c Norm EPS (USD) 13.28c 25.7c 26.33c 3.3c 32.94c Fully diluted norm EPS (USD) 13.28c 25.7c 26.33c 3.3c 32.94c DPS (USD) BVPS (USD) Life/LT EVPS (USD) Life/LT VNBPS (USD) Value of non-life bus. PS (USD)..... Source: Company data, Nomura estimates 3

32 Nomura AIA 2 January 214 Fig. 55: AIA quarterly ANP (USDmn) ANP (LHS) ANP y-y growth (RHS) (3) (9) 1 1Q1 2Q1 3Q1 4Q1 1Q11 2Q11 3Q11 4Q11 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 (%) (1) (2) Fig. 56: AIA quarterly VoNB and VoNB margin (USDmn) VONB (LHS) VONB margins (RHS) Q1 2Q1 3Q1 4Q1 1Q11 2Q11 3Q11 4Q11 1Q12 2Q12 3Q12 4Q12 1Q Q13 3Q13 (%) Fig. 57: AIA - VNB growth by country y-y growth (%) 1H12 2H12 1H (2) Fig. 58: AIA - VNB margin by country y-y growth (%) 1H12 2H12 1H (4) Malaysia Other markets Korea China Hong Kong Thailand Singapore 2 Singapore China Thailand Hong Kong Malaysia Other markets Korea 31

33 Nomura AIA 2 January 214 Valuation methodology and risks Based on a terminal growth rate of 6% and a discount rate of 1%, we have calculated the present value of AIA s VoNB on a perpetual basis to stand at HKD19.1 per share. We then added 213F EV of HKD21.9 per share to derive our price target of HKD41. per share. Our price target implies AIA would trade at 1.88x 213F EV and 16.8x 213F VoNB. The benchmark index for this stock is MSCI HK. Investment risks Investment sentiment could rapidly change along with the inevitable volatility in global financial markets (ie, equity, bond and FX, etc.). Meantime, AIA's geographic diversification implies a longer list of uncertainties associated with its underwriting results which include economic performance, regulation changes, competition, etc. 32

34 Nomura China life insurance 2 January

35 Nomura China life insurance 2 January

36 Nomura China life insurance 2 January 214 Appendix A-1 Analyst Certification We, David Chung and Lucy Feng, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company. Issuer Specific Regulatory Disclosures The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries, and may refer to one or more Nomura Group companies. Materially mentioned issuers Issuer Ticker Price Price date Stock rating Sector rating Disclosures AIA 1299 HK HKD Jan-214 Buy N/A A1 Ping An Insurance Group 2318 HK HKD Jan-214 Buy N/A A1,A2,A3,A1 China Pacific Insurance 261 HK HKD Jan-214 Reduce N/A A1 China Life Insurance 2628 HK HKD Jan-214 Neutral N/A A1,A2,A3,A6 A1 A2 The Nomura Group has received compensation for non-investment banking products or services from the issuer in the past 12 months. The Nomura Group had a non-investment banking securities related services client relationship with the issuer during the past 12 months. A3 The Nomura Group had a non-securities related services client relationship with the issuer during the past 12 months. A6 The Nomura Group expects to receive or intends to seek compensation for investment banking services from the issuer in the next three months. A1 The Nomura Group is a registered market maker in the securities / related derivatives of the issuer. Ping An Insurance Group (2318 HK) Rating and target price chart (three year history) HKD 68.8 (16-Jan-214) Buy (Sector rating: N/A) Date Rating Target price Closing price 3-Aug Nov-12 Neutral Nov Aug-11 Buy Aug For explanation of ratings refer to the stock rating keys located after chart(s) Valuation Methodology Our target price of HKD8 is based on a sum-of-the-parts (SOTP) valuation. For the life business, we apply our target new business multiple of 5.x to the FY15F new business value and then add FY14F embedded value. We value Ping An s P&C business by applying 1x P/E to its FY14F NPAT and securities and trust operations by applying 1x P/E to their FY14F NPAT respectively. We incorporate PAB into our valuation of Ping An by applying a target P/BV multiple of.8x to our FY14F BV forecast. The implied target P/EV is 1.3x, vs historical average of 1.9x and current level of 1.1x. The benchmark index for this stock is MSCI China. 35

37 Nomura China life insurance 2 January 214 Risks that may impede the achievement of the target price Key downside risks include poorer-than-expected execution of the financial conglomerate model, integration with PAB and returns from the A-share market, which would affect sentiment to insurers in general, in our view. Key upside risks are better and earlier-than-expected synergies from the integration of PAB. China Pacific Insurance (261 HK) Rating and target price chart (three year history) HKD (16-Jan-214) Reduce (Sector rating: N/A) Date Rating Target price Closing price 26-Aug Feb-13 Neutral Nov-12 Buy Nov For explanation of ratings refer to the stock rating keys located after chart(s) Valuation Methodology Our target price of HKD26 is premised on a sum-of-the-parts (SOTP) valuation. For the life business, we apply our target NB multiple of 1.x to CPIC Life s FY15F new business value and add its FY14F embedded value. We value CPIC s P&C business by applying 1x P/E to its FY14F NPAT and add the free capital available. The implied target P/EV is 1.x, vs historical average of 1.5x and current level of 1.1x. The benchmark index for this stock is MSCI China. Risks that may impede the achievement of the target price Key upside risks: 1) sales of bancassurance products supporting higher VoNB growth; and 2) stronger-than-expected returns from the A-share market, which would likely boost general sentiment toward insurers. China Life Insurance (2628 HK) Rating and target price chart (three year history) HKD 22.9 (16-Jan-214) Neutral (Sector rating: N/A) Date Rating Target price Closing price 29-Aug Feb-13 Neutral Nov Aug For explanation of ratings refer to the stock rating keys located after chart(s) Valuation Methodology Our target price of HKD2 is premised on a target new business (NB) multiple of 1.x. We apply the target NB multiple to China Life s FY15F new business value and add its FY14F embedded value. The implied target P/EV is 1.x, vs historical average of 2.x and current level of 1.1x. The benchmark index for this stock is MSCI China. 36

38 Nomura China life insurance 2 January 214 Risks that may impede the achievement of the target price Key upside risks include: 1) stronger-than-expected returns from the A-share market; and 2) earlier-than-expected pick-up in momentum in life insurance industry. Key downside risks include: 1) poor returns from the A-share market affecting sentiment to insurers in general; and 2) intense competition leading to a continued squeeze in NB margins for life insurers, especially China Life, which hopes to recapture market share. AIA (1299 HK) Rating and target price chart (three year history) HKD 38. (16-Jan-214) Buy (Sector rating: N/A) Date Rating Target price Closing price 23-Jul Feb Jul Jul-11 Buy Jul Feb For explanation of ratings refer to the stock rating keys located after chart(s) Valuation Methodology Based on a terminal growth rate of 6% and a discount rate of 1%, we have calculated the present value of AIA s VoNB on a perpetual basis to stand at HKD19.1 per share. We then added 213F EV of HKD21.9 per share to derive our price target of HKD41. per share. Our price target implies AIA to trade at 1.88x 213F EV and 16.8x 213F VoNB.The benchmark index for this stock is MSCI HK. Risks that may impede the achievement of the target price Investment sentiment could rapidly change along with the inevitable volatility in global financial markets (ie, equity, bond and FX, etc.). Meantime, AIA's geographic diversification implies a longer list of uncertainties associated with its underwriting results which include economic performance, regulation changes, competition, etc. Rating and target price changes Issuer Ticker Old stock rating New stock rating Old target price New target price Ping An Insurance Group 2318 HK Neutral Buy HKD 6.9 HKD 8. China Pacific Insurance 261 HK Neutral Reduce HKD 28. HKD 26. China Life Insurance 2628 HK Neutral Neutral HKD 21. HKD 2. Important Disclosures Online availability of research and conflict-of-interest disclosures Nomura research is available on Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at or requested from Nomura Securities International, Inc., on If you have any difficulties with the website, please [email protected] for help. The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-us analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account. Nomura Global Financial Products Inc. ( NGFP ) Nomura Derivative Products Inc. ( NDPI ) and Nomura International plc. ( NIplc ) are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. NGFP, NDPI, and NIplc are generally engaged in the trading of swaps and other derivative products, any of which may be the subject of this report. Any authors named in this report are research analysts unless otherwise indicated. Industry Specialists identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have 37

39 Nomura China life insurance 2 January 214 coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. Marketing Analysts identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura s Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector. Distribution of ratings (Global) The distribution of all ratings published by Nomura Global Equity Research is as follows: 42% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 43% of companies with this rating are investment banking clients of the Nomura Group*. 47% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 55% of companies with this rating are investment banking clients of the Nomura Group*. 11% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 26% of companies with this rating are investment banking clients of the Nomura Group*. As at 31 December 213. *The Nomura Group as defined in the Disclaimer section at the end of this report. Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America, and Japan and Asia ex-japan from 21 October 213 The rating system is a relative system, indicating expected performance against a specific benchmark identified for each individual stock, subject to limited management discretion. An analyst s target price is an assessment of the current intrinsic fair value of the stock based on an appropriate valuation methodology determined by the analyst. Valuation methodologies include, but are not limited to, discounted cash flow analysis, expected return on equity and multiple analysis. Analysts may also indicate expected absolute upside/downside relative to the stated target price, defined as (target price - current price)/current price. STOCKS A rating of 'Buy', indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of 'Neutral', indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of 'Reduce', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of 'Suspended', indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as 'Not rated' or shown as 'No rating' are not in regular research coverage. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies. Benchmarks are as follows: United States/Europe/Asia ex- Japan: please see valuation methodologies for explanations of relevant benchmarks for stocks, which can be accessed at: Global Emerging Markets (ex-asia): MSCI Emerging Markets ex-asia, unless otherwise stated in the valuation methodology; Japan: Russell/Nomura Large Cap. SECTORS A 'Bullish' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A 'Neutral' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A 'Bearish' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months. Sectors that are labelled as 'Not rated' or shown as 'N/A' are not assigned ratings. Benchmarks are as follows: United States: S&P 5; Europe: Dow Jones STOXX 6; Global Emerging Markets (ex-asia): MSCI Emerging Markets ex-asia. Japan/Asia ex-japan: Sector ratings are not assigned. Explanation of Nomura's equity research rating system in Japan and Asia ex-japan prior to 21 October 213 STOCKS Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc. A 'Buy' recommendation indicates that potential upside is 15% or more. A 'Neutral' recommendation indicates that potential upside is less than 15% or downside is less than 5%. A 'Reduce' recommendation indicates that potential downside is 5% or more. A rating of 'Suspended' indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company. Securities and/or companies that are labelled as 'Not rated' or shown as 'No rating' are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies. SECTORS A 'Bullish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A 'Neutral' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A 'Bearish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation. Target Price A Target Price, if discussed, reflects in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates. Disclaimers This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('NIplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ( NIHK ), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ( NFIK ), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at Nomura Singapore Ltd. ( NSL ), Singapore (Registration number E, regulated by the Monetary Authority of Singapore); Nomura Australia Ltd. ( NAL ), Australia (ABN

40 Nomura China life insurance 2 January ), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number ; P.T. Nomura Indonesia ( PTNI ), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ( NSM ), Malaysia; NIHK, Taipei Branch ( NITB ), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ( NFASL ), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 4 18, India; Tel: , Fax: ; SEBI Registration No: BSE INB112993, NSE INB , INF , INE , MCX: INE ) and NIplc, Madrid Branch ( NIplc, Madrid ). CNS Thailand next to an analyst s name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited ( CNS ) to provide research assistance services to NSL under a Research Assistance Agreement. CNS is not a Nomura entity. THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION, AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT; (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL; AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE, BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP. Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information. Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice. Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures. This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor s. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ( MSCI ). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. The securities described herein may not have been registered under the US Securities Act of 1933 (the 1933 Act ), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction. This document has been approved for distribution in the UK and European Economic Area as investment research by NIplc. NIplc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. NIplc is a member of the London Stock Exchange. This document does not constitute a personal recommendation within the meaning of applicable regulations in the UK, or take into account the particular investment objectives, financial situations, or needs of individual investors. This document is intended only for investors who are 'eligible counterparties' or 'professional clients' for the purposes of applicable regulations in the UK, and may not, therefore, be redistributed to persons who are 'retail clients' for such purposes. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of

41 Nomura China life insurance 2 January 214 This document has not been approved for distribution to persons other than Authorised Persons, Exempt Persons or Institutions (as defined by the Capital Markets Authority) in the Kingdom of Saudi Arabia ( Saudi Arabia ) or 'professional clients' (as defined by the Dubai Financial Services Authority) in the United Arab Emirates ( UAE ) or a Market Counterparty or Business Customers (as defined by the Qatar Financial Centre Regulatory Authority) in the State of Qatar ( Qatar ) by Nomura Saudi Arabia, NIplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or in Qatar or to any person other than Authorised Persons, Exempt Persons or Institutions located in Saudi Arabia or 'professional clients' in the UAE or a Market Counterparty or Business Customers in Qatar. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are an Authorised Person, an Exempt Person or an Institution in Saudi Arabia or that you are a 'professional client' in the UAE or a Market Counterparty or Business Customers in Qatar and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the UAE or Saudi Arabia or Qatar. NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as , then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version. Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training. Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page: Copyright 214 Nomura International (Hong Kong) Ltd.. All rights reserved. 4

42 Nomura Asian Equity Research Group Hong Kong Nomura International (Hong Kong) Limited 3/F Two International Finance Centre, 8 Finance Street, Central, Hong Kong Tel: Fax: Singapore Nomura Singapore Limited 1 Marina Boulevard Marina Bay Financial Centre Tower 2, #36-1, Singapore 18983, Singapore Tel: Fax: Taipei Nomura International (Hong Kong) Limited, Taipei Branch 17th Floor, Walsin Lihwa Xinyi Building, No.1, Songzhi Road, Taipei 1147, Taiwan, R.O.C. Tel: Fax: Seoul Nomura Financial Investment (Korea) Co., Ltd. 17th floor, Seoul Finance Center, 84 Taepyeongno 1-ga, Jung-gu, Seoul 1-768, Korea Tel: Fax: Kuala Lumpur Nomura Securities Malaysia Sdn. Bhd. Suite No 16.5, Level 16, Menara IMC, 8 Jalan Sultan Ismail, 525 Kuala Lumpur, Malaysia Tel: Fax: India Nomura Financial Advisory and Securities (India) Private Limited Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 4 18, India Tel: Fax: Indonesia PT Nomura Indonesia Suite 29A, 9th Floor, Sentral Senayan II Building Jl. Asia Afrika No. 8, Gelora Bung Karno, Jakarta 127, Indonesia Tel: Fax: Sydney Nomura Australia Ltd. Level 25, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2 Tel: Fax: Tokyo Equity Research Department Financial & Economic Research Center Nomura Securities Co., Ltd. 17/F Urbannet Building, 2-2, Otemachi 2-chome Chiyoda-ku, Tokyo 1-813, Japan Tel: Fax: , Caring for the environment: to receive only the electronic versions of our research, please contact your sales representative.